Role of lymphadenectomy in resectable pancreatic cancer
- 9 September 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Langenbecks Archiv für Chirurgie
- Vol. 405 (7), 889-902
- https://doi.org/10.1007/s00423-020-01980-2
Abstract
Background Pancreatic cancer (PC) remains one of the most devastating malignant diseases, predicted to become the second leading cause of cancer-related death by 2030. Despite advances in surgical techniques and in systemic therapy, the 5-year relative survival remains a grim 9% for all stages combined. The extent of lymphadenectomy has been discussed intensively for decades, given that even in early stages of PC, lymph node (LN) metastasis can be detected in approximately 80%. Purpose The primary objective of this review was to provide an overview of the current literature evaluating the role of lymphadenectomy in resected PC. For this, we evaluated randomized controlled studies (RCTs) assessing the impact of extent of lymphadenectomy on OS and studies evaluating the prognostic impact of anatomical site of LN metastasis and the impact of the number of resected LNs on OS. Conclusions Lymphadenectomy plays an essential part in the multimodal treatment algorithm of PC and is an additional therapeutic tool to increase the chance for surgical radicality and to ensure correct staging for optimal oncological therapy. Based on the literature from the last decades, standard lymphadenectomy with resection of at least ≥ 15 LNs is associated with an acceptable postoperative complication risk and should be recommended to obtain local radicality and accurate staging of the disease. Although radical surgery including appropriate lymphadenectomy of regional LNs remains the only chance for long-term tumor control, future studies specifically assessing the impact of neoadjuvant therapy on extraregional LNs are warranted.This publication has 86 references indexed in Scilit:
- The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival After Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704International Journal of Radiation Oncology*Biology*Physics, 2011
- Pattern of Lymph Node Metastasis Spread in Pancreatic CancerPancreas, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Number of Metastatic Lymph Nodes, but Not Lymph Node Ratio, Is an Independent Prognostic Factor after Resection of Pancreatic CarcinomaJournal of the American College of Surgeons, 2010
- Incidence and Survival of Pancreatic Head and Body and Tail CancersPancreas, 2010
- Pancreatic Resection for M1 Pancreatic Ductal AdenocarcinomaAnnals of Surgical Oncology, 2006
- The Role of Paraaortic Lymph Node Involvement on Early Recurrence and Survival after Macroscopic Curative Resection with Extended Lymphadenectomy for Pancreatic CarcinomaJournal of the American College of Surgeons, 2006
- Lymph node metastasis in carcinoma of the body and tail of the pancreasBritish Journal of Surgery, 1997
- Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasionSurgery, 1995
- Lymph node metastases in carcinoma of the head of the pancreas regionBritish Journal of Surgery, 1995